Mary Miller, Chief Legal Officer of Acrivon Therapeutics, Inc., filed a Form 4 on November 19, 2026, disclosing the automatic sale of 193 shares of common stock on November 17, 2026, to satisfy mandatory tax withholding obligations upon the vesting of restricted stock units.
Key Highlights
- Reporting person: Mary Miller, Chief Legal Officer of Acrivon Therapeutics, Inc.
- Transaction date: November 17, 2026, with 193 shares disposed of under transaction code S.
- Weighted average price: $1.45 per share, reflecting a broker sale of 4,070 shares across a group of employees on that date.
- Purpose: Shares were sold automatically to satisfy mandatory tax withholding requirements upon vesting of restricted stock units.
- Beneficial ownership following transaction: 81,009 shares of common stock held directly.
- Pro rata allocation: Proceeds from the broader 4,070-share broker sale were allocated to participating employees on a pro rata basis.
Acrivon Therapeutics CLO Reports RSU Tax Withholding Sale on November 17, 2026
According to the Form 4 filed with the SEC on November 19, 2026, Mary Miller, serving as Chief Legal Officer of Acrivon Therapeutics, Inc. (NASDAQ:ACRV), reported the disposal of 193 shares of common stock on November 17, 2026. The filing identifies the transaction code as S and states that the shares were "sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."
The filing notes that the price of $1.45 per share represents a weighted average, as the broker sold a total of 4,070 shares on November 17, 2026, on behalf of a group of employees of the issuer, of which Miller was one. The filing further states that "the proceeds of all such sales were allocated to the employees, including the reporting person, on a pro rata basis." The specific 193-share figure reflects Miller's individual allocation from that pooled transaction.
Following the reported transaction, the filing discloses that Miller directly holds 81,009 shares of Acrivon Therapeutics common stock. No derivative securities transactions were reported in Table II of the filing. The form was signed by Adam D. Levy as Attorney-in-Fact on November 19, 2026.
What Was Disclosed
Mary Miller, Chief Legal Officer of Acrivon Therapeutics, filed a Form 4 reporting the automatic sale of 193 shares of common stock at a weighted average price of $1.45 on November 17, 2026, for tax withholding purposes upon RSU vesting, leaving her with 81,009 directly held shares.



Please wait processing your request...